This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 1 week ago
Opinion/decision on a Paediatric investigation plan (PIP): Byetta, Bydureon, Exenatide, Therapeutic area: Endocrinology, -gynacology-fertility-metabolism - European Medicines Agency, 1 month ago
2 images for "Byetta"
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta Exenatide Injection in the United States
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceuticals USA, Inc., (NYSE and TASE:TEVA) announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, ...Pharmacy Choice, 1 month ago Teva settles generic Byetta patent litigation with AstraZeneca PharmaBiz, 1 month ago Teva and AstraZeneca settle Byetta patent fight Seeking Alpha, 2 months ago TEVA PHARMACEUTICAL : Settles Patent Litigation with AstraZeneca Allowing to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States 4 Traders, 2 months ago
Immediately following AstraZeneca's big FluMist setback Thursday, the British pharma has entered into an agreement with Teva that will likely lead to sales losses for another product, Byetta. AstraZeneca and Teva settled patent disputes over the ...CPhI.cn, 1 month ago
A once-weekly subcutaneous injection ofexenatide is being funded on the PBS as part of a $70 million round of new listings. The glucagon-like peptide-1 (GLP-1) analogue has been available on the PBS as a twice-daily subcutaneous injection ...Pharmacy News, 1 week ago Once-weekly diabetes drug gets funding 6minutes.net.au, 1 week ago
Relief is on the way for type 2 diabetics in Australia whose blood sugar test strip subsidy would be removed beginning 2017. A new medicine would not only be subsidised under the Pharmaceutical Benefits Scheme (PBS), but it would also mean less ...International Business Times Australia, 1 week ago Sanofi Should Be Thinking Longer Duration In GLP-1s Seeking Alpha, 3 weeks ago Monthly News Roundup - July 2016 Drugs.com, 3 weeks ago FDA OKs New Injectable Type 2 Diabetes Medication US News & World Report, 3 weeks ago
Achievements of the pharmaceutical giants in the first half of this year have come out, as the global top 10 pharmaceutical enterprises released their 2016Q2 reports in succession. Revenues of top 10 pharmaceutical enterprises in 2016H1- Part 2 ...CPhI.cn, 1 week ago Pharmaceuticals Newsletter - June 20 to 24, 2016 India Infoline, 2 months ago
AstraZeneca (NYSE: AZN ) released its Q2 and first half 2016 results with an upbeat analysis. Q2 results positive and well received AZN is trading at close to a year high, up 8.7% to $34.29 today on good Q2 results. Q2 earnings of $0.83/share ...Seeking Alpha, 3 weeks ago
According to a report by GlobalData, human insulins and many insulin analogs are currently off patent or will soon lose their patents The highly mature Type II diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will ...Express Pharma, 1 month ago Major Players in Type 2 Diabetes Shift Focus to Pricing CPhI.cn, 1 month ago GLOBALDATA : Companies prioritise competitive pricing in type 2 diabetes, says GlobalData 4 Traders, 1 month ago Type 2 Diabetes Market: Competitive Pricing to Offset Patent Expiries PharmaceuticalProcessing, 1 month ago
vTv Therapeutics (NASDAQ: VTVT ) is an emerging biopharmaceutical company that is using a proprietary drug discovery engine called TTP transitional technology to develop novel drugs for common diseases like Alzheimer's disease and type 2 diabetes.Seeking Alpha, 1 month ago
The global type 2 diabetes (T2D) market is projected to reach $58.7bn by 2025, driven by competitive pricing adopted by pharmaceutical companies, according to a GlobalData report. Titled PharmaPoint: Type 2 Diabetes Global Drug Forecast and ...CPhI.cn, 1 month ago Report: Pricing to take precedence as pharmaceutical companies strive to remain profitable within mature type 2 diabetes market Pharmaceutical Technology, 1 month ago
on your WebpageAdd Widget >Get your members hooked!